StitchR makes it possible to deliver larger payloads with current vectors, expanding the list of diseases targetable by gene therapies.

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.

Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is a big problem: size.

The Keeneland November Breeding Stock Sale concluded its nine-day run in Lexington Wednesday with vibrant trade from a diverse buying bench leading to across-the-board increases where were highlighted ...

Neoantigen DNA vaccines are safe and capable of inducing neoantigen-specific immune responses in patients with triple-negative breast cancer, according to a study published online Nov. 14 in Genome ...

A total of 105 head sold for $8,620,500, with an average of $81,325 and a median of $47,500. The median and average were up ...

To determine the type and severity of a cancer, pathologists typically analyze thin slices of a tumor biopsy under a ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset——Joint poster with Bachem demonstrates ...

Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per ...

University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...